Global Size of Research Antibodies Market Will Reach to USD 6.35 Billion by 2028 | CAGR: 6.5%

The global research antibodies market size is expected to reach USD 6.35 billion by 2028 according to a new study by Polaris Market Research.

The significant factors such as the increasing number of R&D activities by the private and government organizations tied with the rising availability of funds offered by the governments for the development of the antibodies may foster the industry growth. In addition, growing incidences of life-threatening and chronic diseases and the widespread of COVID-19 are primarily contributing to the market demand.

(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, Table of Contents, Graphical introduction of regional analysis, Top players in the market with their revenue analysis, and our research methodology.)

For instance, in October 2019, Pascal Biosciences Inc. and Y-Biologics declared their partnership with the aim of developing & discovering numerous bio-specific antibodies for Leukemia. Under the agreement, Pascal Biosciences Inc. will use its antibody products and Y-Biologics to share its new antibody platform technology-ALiCE. Therefore, these varieties of company initiatives for technological advancements in developing antibodies are likely to stimulate industry growth.

Top Market Players

Major participants such Agilnet Technologies, Abcam Plc, Becton Dickinson & Company, Biolegend, Bio-rad Laboratories, Cell Signalling Technology, Danaher Corporation, F.Hoffman-La Roche, Genscript , Illumina,Lonza Group, Merck Millipore, Perkin Elme Inc, Perkinelmer Roche Ltd., Thermo Fisher.are some of the key players operating in the global market.

Request for Discount on this Report Before Purchase @ https://www.polarismarketresearch.com/industry-analysis/research-antibodies-market/request-for-discount-pricing

There are various players and organizations that are launching new products into the global market for the treatment of death-threatening coronavirus. For instance, in June 2021, Regeneron Pharmaceuticals, Inc. declared the approval of its imdevimab and Regeneron’s casirivimab antibody cocktail for the treatment of mild to moderate COVID-19 patients. This approval was done by Japan’s Ministry of Health, Labor and Welfare (MHLW). This marks the first time the antibody cocktail is recognized as Ronaprev in other nations and REGEN-COVTM in the United States, which has collected complete consent in curing the COVID-19.

Browse detail report with in-depth TOC @ https://www.polarismarketresearch.com/industry-analysis/research-antibodies-market

Polaris Market Research has segmented the research antibodies market report on the basis of product, type, technology, source, application, end-use and region:

 Research Antibodies, Product Outlook (Revenue – USD Million, 2018 – 2028)

  • Primary
  • Secondary

  Research Antibodies, Type Outlook (Revenue – USD Million, 2018 – 2028)

  • Monoclonal
  • Polyclonal

Research Antibodies, Technology Outlook (Revenue – USD Million, 2018 – 2028)

  • Immunohistochemistry
  • Immunofluorescence
  • Western Blotting
  • Flow Cytometry
  • Immunoprecipitation
  • ELISA
  • Other Technologies

 Research Antibodies, Source Outlook (Revenue – USD Million, 2018 – 2028)

  • Mouse
  • Rabbit
  • Goat
  • Other Sources

Research Antibodies, Application Outlook (Revenue – USD Million, 2018 – 2028)

  • Infectious Diseases
  • Immunology
  • Oncology
  • Stem Cells
  • Neurobiology
  • Other Applications

 Research Antibodies, End-Use Outlook (Revenue – USD Million, 2018 – 2028)

  • Academic & Research Institutes
  • Contract Research Organizations
  • Pharmaceutical & Biotechnology Companies

About Us:
Polaris Market Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Polaris Market Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We at Polaris are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semiconductors, chemicals, automotive, and aerospace & defense, among different ventures, present globally.